Completed PHASE2 INTERVENTIONAL 2-arm NCT01267292

Psychopharmacology for Cocaine Dependence - Buspirone

Psychopharmacology of Novel Medications for Cocaine Dependence - Buspirone

Sponsor: The University of Texas Health Science Center, Houston

Interventions Buspirone Methylphenidate Placebo for Buspirone Placebo for Methylphenidate

Updated 8 times since 2017 Last updated: May 3, 2017 Started: Mar 31, 2011 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01267292, this PHASE2 trial focuses on Cocaine Dependence and remains completed. Sponsored by The University of Texas Health Science Center, Houston, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2017 — Jun 2018 [monthly]

Completed PHASE2

Phase: PHASE1_PHASE2 → PHASE2
Jan 2017 — Jun 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The University of Texas Health Science Center, Houston

Data source: The University of Texas Health Science Center, Houston

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States